Manish Jain, MD
Rheumatology · Chicago, ILNPI 1417075581
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,351,472 of the $1,884,660 with a category attached, or 71.7%. 40 manufacturers reported payments, led by AbbVie at 36.9% of the total. Reporting peaked in 2019 at $452,629 and has fallen 66.5% since, to $151,778 in 2025. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,626 payments — averaging $717.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$696K
- Amgen$387K
- Lilly USA, LLC$201K
- Novartis$195K
- Bristol Myers Squibb$126K
- Johnson & Johnson$85K
- plus $196K from 34 others
Across 2,193 payments — averaging $15,850 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$9.9M
- Eli Lilly$6.3M
- Astrazeneca UK Limited$4.9M
- Pfizer$4.7M
- Amgen$3.1M
- AstraZeneca$1.7M
- plus $4.2M from 15 others
What the payments were for
- Consulting fees$268,70714%
- Speaking & faculty fees$1,351,47272%
- Travel & lodging$223,76712%
- Food & beverage$40,5532%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$462,417
- Otezla$309,284
- KRYSTEXXA$175,936
- TALTZ$155,994
- COSENTYX$119,600
- Tremfya$111,316
- Skyrizi$108,895
- SIMPONI ARIA$84,286
- BENLYSTA$43,813
- Humira$43,427
- STELARA$43,340
- LUPKYNIS$34,112
- Bimzelx$15,734
- OLUMIANT$13,850
- Tavneos$11,223
- Enbrel$9,943
- SAPHNELO$8,222
- KEVZARA$7,451
- Sotalol Hydrochloride$6,500
- XELJANZ$3,230
How this compares
$1,884,660 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 52 | $395,387 |
| TavneosAvacopan | 13 | $199,074 |
| Enbrel SureclickEtanercept | 19 | $142,195 |
| Humira(Cf) PenAdalimumab | 16 | $137,990 |
| BenlystaBelimumab | 11 | $50,708 |
| KevzaraSarilumab | 11 | $48,947 |
| OtrexupMethotrexate/Pf | 17 | $13,819 |
| Hydroxychloroquine Sulfate | 334 | $9,960 |
| Leflunomide | 147 | $9,347 |
| MethotrexateMethotrexate Sodium | 345 | $8,732 |
| Mycophenolate Mofetil | 19 | $3,488 |
| Prednisone | 320 | $2,533 |
| Sulfasalazine DrSulfasalazine | 41 | $2,165 |
| Colchicine | 37 | $1,456 |
| Methylprednisolone | 60 | $1,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $695,848 | $395,38752 claims |
| AmgenTavneos | $386,567 | $199,07413 claims |
| GSKBenlysta | $44,578 | $50,70811 claims |
| SanofiKevzara | $2,333 | $48,94711 claims |
| Antares Pharma, Inc.Otrexup | $163 | $13,81917 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $21 | $1,45637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 rheumatology providers in Illinois.
Other rheumatology in Chicago
- Theodore PincusChicago$524K
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Robert WoodrickChicago$143K
- Maria SosenkoChicago$87K
- Ailda NikaChicago$74K
- Duncan MooreChicago$71K
- Timothy NiewoldChicago$65K
- Emem Adolf-UbokudomChicago$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.